Patient ID | Age | Gender | Performance status | Diagnoses | Number of vaccinations | Time to progression (Weeks) | Survival (Weeks) | Maximum related toxicity/grade | Response status |
---|---|---|---|---|---|---|---|---|---|
Patient 1 | 71 | Male | 80 | GBM | 2 | 4.2 | 34.6 | ISR/1 | Non-stable |
Patient 2 | 61 | Male | 90 | GBM | 4 | 8 | 12.4 | Non-stable | |
Patient 3 | 42 | Female | 80 | GBM | I | Not evaluable | N/A | Non-stable | |
Patient 4 | 55 | Female | 90 | GBM | 5 | 13.0 | 64.8 | ISR/ 1 | Stable |
Patient 5 | 17 | Male | 70 | GBM | 10 | 30.6 | 53.3 | lSR/1 | Stable |
Patient 6 | 63 | Male | 90 | GBM | 9 | 39.7 | >92 | ISR/1 | Stable |
Patient 7 | 3 | Female | 60 | Epend | 6 | 20.0 | 31.4 | Fat/i | |
ISR/3 | Stable | ||||||||
Patient 8 | 24 | Female | 90 | Med | 5 | 8.0 | >92 | Non-stable | |
Patient 9 | 53 | Male | 80 | GBM | 0 | N/A | N/A | Non-stable | |
Patient 10 | 13 | Female | 90 | PNET | 0 | N/A | N/A | Non-stable | |
Patient 11 | 49 | Male | 80 | GBM | 0 | N/A | N/A | Non-stable | |
Patient 12 | 48 | Male | 80 | GBM | 0 | N/A | N/A | Non-stable |